About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Safety, Tolerability and Efficacy of BFH772 in Rosacea Patients

NCT01449591·6 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Novartis Pharmaceuticals

Age

18–65

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Have persistent facial erythema on the cheeks of at least moderate severity.
Women must not be able to bear children

You may not be if

Have more than 12 inflammatory lesions on the face
Previous treatment of facial skin with lasers or electrocauterisation within 2 months prior to entering the study

The record

StatusCompleted

PhasePhase 2

Taking part36

StartedSep 2011

UpdatedFeb 21, 2021

Conditions

Erythemato-telangiectatic Rosacea

Where6

Novartis Investigative Site
Hot Springs, Arkansas, United States
Novartis Investigative Site
Ann Arbor, Michigan, United States
Novartis Investigative Site
Paramus, New Jersey, United States

Clareo Health | Safety, Tolerability and Efficacy of BFH772 in Rosacea Patients